Remedent Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Remedent Inc (REMI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Remedent Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 219,078M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+19.6% annualized vs trailing 12 months), vs decelerating (-9.3%) for its tracked peer group.
- Growth: Remedent Inc generated 28.8% revenue growth year over year in Q3 2020, vs 9.0% for its tracked competitors combined.
- Profitability: Its 29.2% net margin compares with 13.5% for the peer group.
- Peer revenue share: Remedent Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.11M compares with $0.75M for the peer group (0.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
REMI Sales vs. its Competitors, Q3 2020
Remedent Inc reported revenue growth of 28.77 % year on year in Q3 2020, above its competitors' combined revenue growth of 8.97 %.
With a net margin of 29.16 %, Remedent Inc achieved higher profitability than its competitors (13.53 %).
Remedent Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Remedent Inc vs. its Competitors, Q3 2020
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Remedent Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Remedent Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Remedent Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 15.0% year over year, combined, vs 28.8% for Remedent Inc. Remedent Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Remedent Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Remedent Inc | No | No | No | Yes |
| Competitors combined (7) | ||||
| Similar Growth & Profitability (8) | 25.00 % (2 of 8) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
REMI Stock Performance relative to its Competitors
REMI Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Horizon Kinetics Holding Corporation | 282.9% | Outperformed |
| 2 | Johnson and Johnson | 282.9% | Outperformed |
| 3 | Church and Dwight Co Inc | 282.9% | Outperformed |
| 4 | Colgate palmolive Company | 282.9% | Outperformed |
| 5 | Procter and Gamble Co | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Remedent Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Remedent Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Remedent Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Remedent Inc | 0.01 | 1.13 |
| Johnson and Johnson | 663,585.20 | 97,929.00 |
| Procter and Gamble Co | 361,061.51 | 87,032.00 |
| Colgate palmolive Company | 69,371.74 | 21,046.00 |
| Church and Dwight Co Inc | 22,776.68 | 6,228.60 |
| The Clorox Company | 9,915.90 | 6,760.00 |
| SUBTOTAL | 1,126,739.09 | 219,079.07 |
Sign in to see all competitors of Remedent Inc .
Sources: Remedent Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Remedent Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Remedent Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Johnson and Johnson | Oncology 29.26 % |
| Procter and Gamble Co | Fabric & Home Care 34.83 % |
| Colgate palmolive Company | Oral, Personal and Home Care 77.71 % |
| Church and Dwight Co Inc | Consumer Domestic 75.54 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Remedent Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Remedent Inc | 0 | 112,883 | -29,336 |
| Johnson and Johnson | 663,585 | 695,518 | 149,411 |
| Procter and Gamble Co | 361,062 | 836,846 | 155,231 |
| Colgate palmolive Company | 69,372 | 626,369 | 64,345 |
| Church and Dwight Co Inc | 22,777 | 1,122,270 | 134,198 |
| The Clorox Company | 9,916 | 768,182 | 87,500 |
| PEERS TOTAL | 1,126,739 | 748,051 | 139,579 |
Remedent Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Johnson and Johnson | United States 57.42 % |
| Procter and Gamble Co | Non-US 52.05 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Remedent Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 222 companies in Remedent Inc's industry classification, broader than the peer set above. Market cap in millions of $.Remedent Inc ranks #0 of 222 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 587, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 145,832 | 13.38 % |
| 2 | Medtronic Plc | 113,372 | 10.40 % |
| 3 | Stryker Corp | 105,405 | 9.67 % |
| 4 | 3m Company | 88,542 | 8.12 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Dexcom Inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Alcon inc | 1,234 | 5.2% |
| 0 | Remedent Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Remedent Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-05-29.
Remedent Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (288 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 65.38 % | 53.35 % (avg) | +12.0 pp |
| Operating Margin | -9.45 % | industry median | -2.5 pp |
| EBITDA Margin | -17.22 % | -6.82 % (avg) | -10.4 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 5.43 % (avg) | -5.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Remedent Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (288 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 34.6x | - |
| EV / EBITDA | - | 19.7x | - |
| P/B | 0.7x | 4.7x | -4.1x |
| Return on Equity | -6.37 % | industry aggregate | -14.58 % |
| Return on Invested Capital | -1.15 % | -2.32 % (avg) | 1.17 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Remedent Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | -21.78 % | 4.21 % | -20.59 % | 14.34 % | -38.79 % | -27.69 % | -7.32 % |
| Operating Margin | -0.64 % | -19.41 % | 9.54 % | -12.96 % | -37.91 % | -43.34 % | -42.07 % | -9.45 % |
| Return on Invested Capital | -0.55 % | -10.41 % | 5.95 % | -5.85 % | -15.74 % | -11.58 % | -4.85 % | -1.15 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Remedent Inc's Strategic Group Map
Every company in Remedent Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Remedent Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Remedent Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 587 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 5.43 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Remedent Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Remedent Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Remedent Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Remedent Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Remedent Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+19.6% annualized vs trailing 12 months).
Weaknesses
- Return on equity 14.6 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-9.3% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Remedent Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Remedent Inc | 0.04 | 0.24 | 0.00 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Procter and Gamble Co | 0.25 | 0.71 | 0.71 |
| Colgate palmolive Company | 0.21 | 0.95 | 12.14 |
| Church and Dwight Co Inc | 0.26 | 1.13 | 0.53 |
| The Clorox Company | 0.18 | 0.82 | 9.85 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Remedent Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Remedent Inc | Q4 2020 | +28.8 % | - |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Procter and Gamble Co | Q2 2026 | +1.5 % | -15.0 % |
| Colgate palmolive Company | Q2 2026 | +4.9 % | -7.0 % |
| Church and Dwight Co Inc | Q2 2026 | +1.6 % | +6.2 % |
| The Clorox Company | Q1 2026 | +0.1 % | +0.0 % |
| PEERS TOTAL | +4.1 % | -6.6 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Remedent Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Remedent Inc | Q4 2020 | +35.8 % | - |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Procter and Gamble Co | Q2 2026 | +2.7 % | +2.7 % |
| Colgate palmolive Company | Q2 2026 | +1.2 % | +18.5 % |
| Church and Dwight Co Inc | Q2 2026 | -2.7 % | +32.9 % |
| The Clorox Company | Q1 2026 | +2.6 % | - |
Remedent Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Remedent Inc | - | - | - |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Procter and Gamble Co | 12.72% | 17.81% | 30.05% |
| Colgate palmolive Company | 12.86% | 19.90% | 325.73% |
| Church and Dwight Co Inc | 8.24% | 8.83% | 17.78% |
| The Clorox Company | 13.34% | 19.55% | 257.96% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Remedent Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Remedent Inc | - | 0.01 |
| Johnson and Johnson | 31.48 | 6.78 |
| Procter and Gamble Co | 22.62 | 4.15 |
| Colgate palmolive Company | 34.26 | 3.30 |
| Church and Dwight Co Inc | 30.85 | 3.66 |
| The Clorox Company | 13.24 | 1.47 |
| PEERS AVERAGE | 27.56 | 5.14 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.